Payment overview · 2025
General Payments
$1,087.86
74 reported records · 14 companies
Healthcare provider profile · identity verified
Julia Bates, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WINSTON SALEM, NC · NPI 1720350887
Verified facts
What the public records show
CMS Open Payments records show Julia Bates, FNP-BC received $1,087.86 in general payments during 2025 across 74 reported records.
ABBVIE INC. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Zubsolv by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $325.71 | 29.9% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $215.62 | 19.8% | 19 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $206.68 | 19.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.17 | 4.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.84 | 3.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.37 | 3.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.21 | 3.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $36.17 | 3.3% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $35.23 | 3.2% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $34.56 | 3.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.66 | 1.6% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.28 | 1.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.21 | 1.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $15.15 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,087.86 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $272.93 | 21 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $263.40 | 20 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $210.22 | 18 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $206.68 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $179.18 | 16 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.78 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.17 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.84 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.17 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $5.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $5.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $5.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 667 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 581 | 78 |
| Oxycodone Hcl | Oxycodone Hcl | 434 | 64 |
| Gabapentin | Gabapentin | 193 | 47 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 149 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 134 | 14 |
| Pregabalin | Pregabalin | 129 | 22 |
| Prednisone | Prednisone | 96 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 81 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 13 |
| Tramadol Hcl | Tramadol Hcl | 65 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | 17 |
| Lisinopril | Lisinopril | 43 | 19 |
| Metformin Hcl | Metformin Hcl | 43 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 40 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 18 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 29 | 29 |
| Baclofen | Baclofen | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Carvedilol | Carvedilol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,087.86 · 74 records | ABBVIE INC. | ABRYSVO, BREZTRI, Belbuca, COMIRNATY, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, MOUNJARO, NURTEC ODT, PREVNAR 20, QULIPTA, RELISTOR, REXULTI, TONMYA, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, Zubsolv | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error